ClinicalTrials.gg
Status unknownNCT04792723Updated Mar 11, 2021

Pharmacokinetic and Pharmacodynamic Study of a Novel Sublingual Aspirin Tablet

A Phase 1 interventional study of Sublingual aspirin and Oral aspirin in Cardiovascular Diseases, sponsored by Vita Green Health Products Co. Ltd. Status unknown. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-11.

Sponsored by Vita Green Health Products Co. Ltd · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The objective of the study is to compare the pharmacokinetics and pharmacodynamics of a new sublingual formulation of aspirin with that of oral aspirin when administered to healthy volunteers under fasting conditions. The test product is sublingual aspirin 80 mg manufactured by Vita Green Health Products Co. Ltd, Hong Kong and the reference product is oral aspirin 80mg tablet manufactured by Synco (HK) Ltd, Hong Kong.

02

Conditions studied

  • Cardiovascular Diseases
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's planned enrollment of 24 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

This is the only study on the registry with Vita Green Health Products Co. Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, 18 to 55 years of age
  2. between 18-27kg/m2
  3. Accessible vein for blood sampling
  4. High probability for compliance and completion of the study
  5. No significant abnormalities in general physical examination
  6. Subjects must agree to take effective methods to prevent his partner pregnant during the time of first dose of study medication until one week of last dose administration

Exclusion criteria

Exclusion Criteria:

  1. History of hepatic, renal, biliary, cardiovascular, gastrointestinal, haematological and other chronic and acute diseases within 3 months prior to screening
  2. abnormality in physical examination, evaluation, urine test, blood chemistry or haematological test at the discretion of the investigator
  3. Positive results for at screening
  4. Moderate smoker (on average more than 2 cigarettes a day within 1 month prior to the start of first dosing)
  5. Moderate consumption of alcohol (on average more than one drink per day within 1 month prior to start of first dosing)
  6. Blood donation of more than 350 ml within 4 weeks prior to start of first drug dosing
  7. Treatment of aspirin within 4 weeks before first dosing
  8. Volunteer in any other clinical drug study within 2 months prior to start of first dosing
  9. to aspirin or other drug in its class
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Healthy volunteer

    Sublingual or oral aspirin 80mg tablet, single dose, two-treatment, two-period, two-sequence, randomized, crossover design, with washout 1-2 weeks

    Drug: Sublingual aspirin · Drug: Oral aspirin

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma-concentration time data of salicylic acid

    area under the plasma concentration-time curve from time zero to last measurable concentration time point for sublingual versus oral aspirin 80mg

    Time frame: pre dose and up to 24 hour post dose

Secondary outcomes

  1. Peak plasma concentration of salicylic acid

    Peak plasma concentration for sublingual versus oral aspirin 80mg

    Time frame: pre dose and up to 24 hour post dose

  2. Time to reach peak plasma concentration of salicylic acid

    Tmax of sublingual versus oral aspirin 80mg

    Time frame: pre dose and up to 24 hour post dose

  3. Terminal phase elimination rate constant of salicylic acid

    Terminal phase elimination rate constant of sublingual versus oral aspirin 80mg

    Time frame: pre dose and up to 24 hour post dose

  4. Terminal elimination half-life of salicylic acid

    Terminal elimination half-life of sublingual versus oral aspirin 80mg

    Time frame: pre dose and up to 24 hour post dose

  5. Plasma concentration time data of thromboxane B2

    Area under the curve for sublingual versus oral aspirin 80mg

    Time frame: pre dose and up to 24 hour post dose

  6. Platelet aggregation by impedance aggregometry

    Differences in platelet aggregation with sublingual versus oral aspirin 80mg

    Time frame: pre dose and up to 360 minutes post dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2021; primary completion for Jul 2021, 3 months later.

Of 53 industry-sponsored phase 1 interventional studies under Cardiovascular Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's planned 3 months is close to that.

Counting every sponsor, half of 96 studies reached it within 15 months; a quarter within 3 and three quarters within 45.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2021
First posted
Mar 11, 2021
StartEst.
Mar 5, 2021
Primary completionEst.
Jul 1, 2021
CompletionEst.
Sep 1, 2021
Last update
Mar 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04792723
Lead sponsor
Vita Green Health Products Co. Ltd
Responsible party
Dr. Elaine Chow (Clinical Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Mar 11, 2021
Start date
Mar 5, 2021 (estimated)
Primary completion
Jul 1, 2021 (estimated)
Completion
Sep 1, 2021 (estimated)
Last update
Mar 11, 2021

Study contacts

Rolley Lee
Contact
rolley.lee@vitagreen.com
+852 29035983
Elaine Chow
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion